PHVS — Pharvaris N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1830487 ·
Netherlands
Last close
$31.12
Market Cap
$2.18B
52W High
$43.25
52W Low
$20.65
ADV30
949,482
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -50,788,287 | -47,842,729 | 328,667,391 | 318,282,453 | 27,856,887 |
| Mar 2026 | 0 | — | -44,272,001 | -39,200,673 | 259,788,041 | 246,957,998 | 23,455,647 |
| Dec 2025 | 0 | — | -47,599,025 | -46,740,853 | 301,454,999 | 291,678,888 | 30,180,665 |
| Sep 2025 | 0 | — | -39,664,499 | -37,137,035 | 338,896,201 | 329,285,629 | 26,655,561 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-147,367,985
Investing CF
$-55,713
Financing CF
$160,621,152
CapEx
$-233,352
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.88
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-619,536,888
Inventory
—
Receivables
$4,975,314
ST Investments
—
EBIT TTM
$-171,908,622
Pretax Income TTM
$-166,600,906
Interest Exp TTM
—
Analysts
14
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -169,822,932 | -175,699,397 | 301,454,999 | 30,180,665 | 271,274,334 | -137,073,634 |
| Dec 2024 | 0 | -145,688,167 | -134,221,527 | 291,374,765 | 23,614,024 | 267,760,741 | -120,130,191 |
| Dec 2023 | 0 | -96,913,620 | -100,875,068 | 398,694,465 | 14,646,062 | 384,048,403 | -93,049,093 |
| Dec 2022 | 0 | -86,714,608 | -76,332,557 | 167,732,983 | 18,473,953 | 149,259,030 | -67,162,634 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.15
Max Pain — expiry 2026-10-16
max pain strike: $40.00 · spot: $31.69 · call oi: 7,333 · put oi: 14,275
Expected Move to 2026-10-16:
±$3.10
(9.78%) —
implied range
$28.59 –
$34.79
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMNM | Immunome Inc. | $2.19B | $19.31 | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.16B | $16.22 | — |
| VERA | Vera Therapeutics, Inc. | $2.14B | $29.73 | — |
| BHC | Bausch Health Companies Inc. | $2.26B | $6.04 | — |
| PBH | Prestige Consumer Healthcare Inc. | $2.27B | $47.87 | — |
News headlines (Yahoo Finance, 1h cache)
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
2026-10-08 22:35 · Yahoo
Could Real-World HAE Oral Preference Data Be a Pivotal Signal for Pharvaris' (PHVS) Strategy?
2026-10-08 15:10 · Yahoo
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
2026-10-05 10:50 · Yahoo
What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?
2026-09-19 15:12 · Yahoo
Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win?
2026-09-10 23:25 · Yahoo
Pharvaris Could Gain Hereditary Angioedema Market Share on Deucrictibant XR Data, RBC Says
2026-09-09 15:18 · Yahoo
Pharvaris charts approval course for swelling disorder drug on Phase III win
2026-09-09 11:33 · Yahoo
Biotech Stocks, With 'Blowout' And 'Bull Case' Results, Rocket To Record Highs
2026-09-08 20:24 · Yahoo
Pharvaris Shares Surge 27% After Deucrictibant Phase 3 Trial Meets Primary Endpoint
2026-09-08 12:56 · Yahoo
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
2026-09-08 10:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.